HbA1c normal but OGTT high is a combination that can seem contradictory, yet it carries genuine clinical significance. Rather than one test being incorrect, the discrepancy reflects the fact that HbA1c measures average blood glucose over two to three months, whilst the oral glucose tolerance test (OGTT) assesses how efficiently your body clears a concentrated glucose load. A raised OGTT result — even alongside a reassuring HbA1c — may indicate early impaired glucose tolerance, non-diabetic hyperglycaemia, or gestational diabetes. Understanding why these results diverge, and what action to take, is essential for protecting your long-term metabolic health.

What It Means When HbA1c Is Normal but OGTT Results Are High

A normal HbA1c alongside a high OGTT result indicates the body struggles to clear a glucose load efficiently, even when average glucose levels appear controlled — an early sign of impaired glucose tolerance or non-diabetic hyperglycaemia.

Have any more questions about this? Message our pharmaceutical team to get more info →

Receiving a normal HbA1c result alongside a high oral glucose tolerance test (OGTT) result can feel confusing and contradictory. However, this combination is more common than many people realise, and it carries important clinical significance. Rather than one test being 'wrong', the discrepancy often reflects the fact that these two investigations measure fundamentally different aspects of blood glucose regulation.

A normal HbA1c — typically below 42 mmol/mol (6.0%) — suggests that your average blood glucose over the preceding two to three months has been within an acceptable range. However, a raised OGTT result indicates that your body is struggling to process a concentrated glucose load efficiently, even if your day-to-day glucose levels appear controlled. This pattern can be an early warning sign of non-diabetic hyperglycaemia (NDH) — the UK clinical term that encompasses impaired glucose tolerance and impaired fasting glucose, sometimes also referred to as prediabetes — or, in pregnancy, gestational diabetes.

It is important not to dismiss a high OGTT result simply because the HbA1c appears reassuring. The OGTT is the recommended diagnostic test for detecting early-stage glucose dysregulation in specific populations, including pregnant women, those with risk factors for type 2 diabetes, and individuals with conditions that affect red blood cell turnover (which can make HbA1c unreliable). Importantly, a two-hour OGTT result of 11.1 mmol/L or above, or a fasting plasma glucose of 7.0 mmol/L or above, meets the WHO diagnostic threshold for diabetes — not merely impaired glucose tolerance — and would require clinical confirmation and follow-up. If you have received conflicting results, your GP or specialist will be best placed to interpret them in the context of your full clinical picture.

(WHO diagnostic criteria 1999/2006; NICE CKS: Type 2 diabetes in adults; NHS Diabetes — Diagnosis)

How HbA1c and the Oral Glucose Tolerance Test Measure Blood Sugar Differently

HbA1c measures average blood glucose over 2–3 months via red blood cell glycation, whilst the OGTT dynamically assesses post-load glucose clearance, making it better at detecting early postprandial hyperglycaemia.

Understanding why these two tests can produce different results requires a brief look at what each one actually measures. HbA1c reflects the proportion of haemoglobin molecules in red blood cells that have become glycated (coated with glucose) over time. Because red blood cells survive for approximately 90–120 days, HbA1c provides a retrospective snapshot of average blood glucose over roughly the past two to three months. It does not capture short-term spikes or the body's acute response to glucose intake. In the UK, HbA1c is the first-line test for diagnosing type 2 diabetes in most adults, except where it is known to be unreliable (for example, in pregnancy or in conditions affecting red blood cell turnover).

The oral glucose tolerance test (OGTT), by contrast, is a dynamic test. Under the standard UK protocol (aligned with NICE NG3 and WHO guidance), it involves:

• Fasting overnight (typically for 8–10 hours)

• Having a fasting venous plasma glucose measurement taken

• Drinking a standardised glucose solution (75 g of anhydrous glucose dissolved in water)

• Having a further venous plasma glucose measurement taken at two hours post-ingestion

The OGTT specifically assesses how effectively the body clears a glucose load from the bloodstream — a process dependent on insulin secretion and peripheral insulin sensitivity. A person may maintain acceptable average glucose levels (reflected in a normal HbA1c) yet still demonstrate impaired post-load glucose clearance on an OGTT, indicating early dysfunction in insulin response.

This distinction is clinically meaningful. The OGTT is particularly useful for detecting postprandial hyperglycaemia — elevated glucose after meals — which can precede changes in fasting glucose or HbA1c by several years. NICE and the World Health Organisation (WHO) both recognise the OGTT as the recommended diagnostic test for gestational diabetes and impaired glucose tolerance; it is not routinely used for diagnosing type 2 diabetes outside these specific contexts.

(NICE NG3: Diabetes in pregnancy; WHO diagnostic criteria 1999/2006; NICE CKS: Type 2 diabetes in adults)

Common Reasons for a Discrepancy Between HbA1c and OGTT

Discrepancies most commonly arise from conditions affecting red blood cell lifespan (such as anaemia or haemoglobin variants), early insulin resistance where compensatory insulin keeps average glucose normal, or ethnicity-related differences in insulin sensitivity.

Several physiological and clinical factors can explain why HbA1c may appear normal whilst the OGTT reveals elevated glucose levels. Understanding these reasons helps contextualise the results rather than viewing them as contradictory.

Conditions affecting red blood cell lifespan or haemoglobin structure are among the most significant causes. HbA1c can be unreliable in conditions such as:

• Haemolytic anaemia

• Iron deficiency anaemia — this typically raises HbA1c; correction of iron deficiency can subsequently lower it

• Haemoglobin variants (e.g., sickle cell trait, thalassaemia) — these may interfere with specific HbA1c assay methods; local laboratory method notes should be checked

• Recent blood transfusion or acute blood loss

• Chronic kidney disease (uraemia can affect glycation)

• Erythropoietin (EPO) therapy

• Certain medications causing haemolysis (e.g., dapsone)

• HIV infection or post-splenectomy states

In these situations, the OGTT or fasting plasma glucose is a more reliable diagnostic tool than HbA1c.

Early or mild insulin resistance is another common explanation. In the early stages of glucose dysregulation, the pancreas may compensate by producing extra insulin, keeping fasting and average glucose levels within normal limits. However, this compensatory mechanism may be insufficient to handle a large glucose challenge, resulting in a raised two-hour OGTT value despite a normal HbA1c.

Ethnicity and body composition also play a role. Research has shown that individuals of South Asian, Black African, or Black Caribbean heritage may develop insulin resistance and impaired glucose tolerance at lower body mass indices than white European populations, sometimes before HbA1c rises. NICE guidance recommends lower BMI thresholds for intervention in Black, Asian, and other minority ethnic groups. Additionally, age-related changes in insulin secretion and sensitivity can produce similar discrepancies in older adults.

There is no single definitive explanation for every case, and clinical interpretation should always be individualised.

(WHO 2011 Use of HbA1c in the diagnosis of diabetes mellitus; NICE PH46: BMI — preventing ill health among Black, Asian and other minority ethnic groups; NHS/Diabetes UK information on factors affecting HbA1c accuracy)

When a High OGTT Result May Indicate Non-Diabetic Hyperglycaemia or Gestational Diabetes

A two-hour OGTT result of 7.8–11.0 mmol/L indicates impaired glucose tolerance; in pregnancy, NICE NG3 diagnoses gestational diabetes at ≥7.8 mmol/L at two hours or a fasting glucose ≥5.6 mmol/L.

A raised OGTT result — even in the presence of a normal HbA1c — may indicate non-diabetic hyperglycaemia (NDH) (also referred to as prediabetes, encompassing impaired glucose tolerance or impaired fasting glucose) or, in pregnancy, gestational diabetes mellitus (GDM). Both conditions carry important health implications and warrant prompt clinical attention.

According to WHO and NICE criteria, impaired glucose tolerance (IGT) is diagnosed when the two-hour venous plasma glucose following a 75 g OGTT falls between 7.8 and 11.0 mmol/L, with a fasting glucose below the diabetic threshold. A two-hour result of 11.1 mmol/L or above, or a fasting plasma glucose of 7.0 mmol/L or above, meets the WHO diagnostic threshold for diabetes; if the person is asymptomatic, a confirmatory test on a separate day is required before a diagnosis of diabetes is made. IGT is a recognised prediabetic state associated with an increased risk of progressing to type 2 diabetes and cardiovascular disease, and it may not be captured by HbA1c alone, particularly in its early stages.

In pregnancy, the diagnostic thresholds differ. NICE guideline NG3 defines gestational diabetes as:

• A fasting plasma glucose of 5.6 mmol/L or above, or

• A two-hour plasma glucose of 7.8 mmol/L or above following a 75 g OGTT

Once GDM is diagnosed, NICE NG3 recommends self-monitoring of blood glucose with targets of: fasting ≤5.3 mmol/L; one hour after meals ≤7.8 mmol/L; two hours after meals ≤6.4 mmol/L.

GDM is associated with risks including macrosomia (large baby), preterm birth, pre-eclampsia, and an increased likelihood of the mother developing type 2 diabetes later in life. Because HbA1c is not recommended as a diagnostic tool for GDM — partly due to physiological changes in red blood cell turnover during pregnancy — the OGTT remains the standard screening method.

After delivery, women who have had GDM should be offered a fasting plasma glucose test (or OGTT) at 6–13 weeks postpartum to exclude persistent diabetes, followed by annual HbA1c or fasting plasma glucose thereafter, given their elevated long-term risk.

If your OGTT result meets any of these thresholds, your healthcare team will discuss the diagnosis clearly with you and outline the next steps for monitoring and management.

(NICE NG3: Diabetes in pregnancy; WHO diagnostic criteria 1999/2006; NHS Gestational diabetes page)

Next Steps and Further Testing Recommended by NHS Guidelines

Non-pregnant individuals with a raised OGTT may be referred to the NHS Diabetes Prevention Programme and monitored with annual HbA1c or fasting plasma glucose; pregnant women with GDM are referred to a joint obstetric-diabetes clinic.

If your OGTT result is raised but your HbA1c is normal, your GP or specialist will typically recommend a structured follow-up plan in line with NHS and NICE guidance. The appropriate next steps will depend on whether you are pregnant, your overall risk profile, and the degree of elevation in your OGTT result.

For non-pregnant individuals, NICE guideline PH38 (Type 2 Diabetes: Prevention in People at High Risk) recommends that people identified with non-diabetic hyperglycaemia (NDH) are referred to the NHS Diabetes Prevention Programme (NHS DPP) — a structured, evidence-based lifestyle intervention. Eligibility for the NHS DPP is based on nationally defined criteria, which include an HbA1c of 42–47 mmol/mol, a fasting plasma glucose of 5.5–6.9 mmol/L, or an equivalent NDH result on OGTT; local referral criteria may vary slightly. Your GP may also:

• Monitor with annual HbA1c or fasting plasma glucose — repeating the OGTT is not routine practice in the UK outside pregnancy unless there is a specific clinical reason

• Assess cardiovascular risk factors including blood pressure, lipid profile, and BMI

• Investigate for underlying causes of HbA1c inaccuracy (e.g., full blood count, haemoglobin variant testing)

For pregnant women diagnosed with GDM following an OGTT, NICE NG3 recommends:

• Referral to a joint obstetric-diabetes clinic

• Initiation of blood glucose self-monitoring

• Dietary and lifestyle advice from a specialist dietitian

• Consideration of pharmacological treatment (metformin or insulin) if glucose targets are not met through lifestyle measures alone

• Postpartum testing at 6–13 weeks and ongoing annual surveillance thereafter

When to contact your GP promptly:

• If you experience symptoms of hyperglycaemia (excessive thirst, frequent urination, unexplained fatigue, or blurred vision)

• If you are pregnant and awaiting follow-up after an abnormal OGTT

• If you have additional risk factors such as a family history of type 2 diabetes, obesity, or polycystic ovary syndrome (PCOS)

Early intervention at the NDH stage has been shown to significantly reduce the risk of progression to type 2 diabetes.

(NICE PH38: Type 2 diabetes: prevention in people at high risk; NICE NG3: Diabetes in pregnancy; NHS Diabetes Prevention Programme guidance)

Managing Your Blood Sugar After an Abnormal OGTT Result

Management centres on reducing refined carbohydrates, achieving at least 150 minutes of moderate-intensity exercise weekly, and weight management where relevant; metformin may be considered off-label in high-risk individuals per NICE PH38.

An abnormal OGTT result — even without a concurrent rise in HbA1c — is a meaningful signal that your body's glucose regulation warrants attention. The encouraging news is that lifestyle interventions at this stage are highly effective and can, in many cases, reverse impaired glucose tolerance entirely.

Dietary modifications are central to management. Evidence supports a diet that:

• Reduces refined carbohydrates and added sugars

• Emphasises low-glycaemic index (GI) foods such as wholegrains, legumes, and non-starchy vegetables

• Includes adequate dietary fibre, which slows glucose absorption

• Limits ultra-processed foods and sugary beverages

A referral to a registered dietitian can provide personalised guidance, particularly for those with complex dietary needs. In pregnancy, dietary changes should be guided by a specialist dietitian or diabetes team; the aim is glycaemic control rather than weight loss, and any dietary plan should follow specialist advice.

Physical activity plays an equally important role. Regular moderate-intensity exercise — such as brisk walking, cycling, or swimming — improves peripheral insulin sensitivity and helps the muscles utilise glucose more effectively. In line with UK Chief Medical Officers' (CMO) Physical Activity Guidelines, adults are advised to aim for at least 150 minutes of moderate-intensity aerobic activity per week, undertake muscle-strengthening activities on at least two days per week, and reduce prolonged periods of sitting.

Weight management, where relevant, is also beneficial. Even a modest reduction in body weight of 5–10% has been shown in clinical trials to significantly improve glucose tolerance and reduce diabetes risk.

Smoking cessation and keeping alcohol within recommended limits (no more than 14 units per week, spread across the week) are also advisable for overall metabolic and cardiovascular health.

For those enrolled in the NHS Diabetes Prevention Programme, structured group support, behavioural coaching, and ongoing monitoring are provided.

Metformin may be considered in certain high-risk individuals with NDH — for example, those with a BMI of 35 kg/m² or above, those aged under 60 with additional risk factors, or those whose HbA1c or fasting plasma glucose continues to rise despite lifestyle changes. It is important to note that metformin use for NDH is off-label in the UK (its licensed indication is for type 2 diabetes); any decision to prescribe it in this context should be made by a clinician in line with NICE PH38 guidance and with the patient's informed agreement.

Regular follow-up with your GP remains essential to track progress, repeat relevant tests (typically annual HbA1c or fasting plasma glucose), and adjust your management plan as needed. With the right support, many people with a raised OGTT result and normal HbA1c can successfully protect their long-term metabolic health.

(NICE PH38: Type 2 diabetes: prevention in people at high risk; UK CMO Physical Activity Guidelines; MHRA/EMC metformin SmPC; NHS healthy eating and diabetes prevention pages)

Frequently Asked Questions